Are There Any Potential Biomarkers for Kinesin Activity in Cancer?
Research is ongoing to identify biomarkers that can predict response to kinesin inhibitors. Overexpression of certain kinesins, such as KIF14 and KIF23, may serve as potential biomarkers for selecting patients who could benefit from kinesin-targeted therapies. Additionally, monitoring changes in the expression levels of kinesins during treatment could provide insights into therapeutic efficacy.
